|Articles|October 20, 2015
New Drug Safety Alliance, Website to Educate on REMS
The Patients Alliance for Drug Safety Protections is comprised of 20 public health, patient advocacy, health professional and disease organizations. To underscore the value of REMS to public health, the Alliance unveiled a new online resource.
Advertisement
A new alliance has launched to educate the public, policymakers and other key stakeholders about Risk Evaluation and Mitigation Strategies (REMS). The Patients Alliance for Drug Safety Protections is comprised of 20 public health, patient advocacy, health professional and disease organizations. To underscore the value of REMS to public health, the Alliance unveiled a new online resource, www.drugprotections.org that translates the latest facts about the REMS program in layman's terms. Designed for ease of use, the online hub summarizes the history and purpose of REMS, what REMS entails and the number of medicines now marketed with a REMS. In addition, the website provides links to information about REMS from FDA and other reputable source and will serve as a clearinghouse for the coalition's policy materials.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
4
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
5